Literature DB >> 8123617

Impact of enucleation versus plaque radiotherapy in the management of juxtapapillary choroidal melanoma on patient survival.

P De Potter1, C L Shields, J A Shields, J R Cater, D J Tardio.   

Abstract

The records of 265 consecutive patients with juxtapapillary choroidal melanoma were reviewed and a statistical non-randomised retrospective study was performed to evaluate the risk for metastasis and compare the survival rate of patients treated with plaque radiotherapy or enucleation. To obtain sufficient overlap between the enucleation and plaque radiotherapy, the statistical analysis was limited to an adjusted subgroup of 127 patients who met eligibility criteria for plaque radiotherapy and who had a minimum of 3 years of follow up after treatment. In the adjusted subgroup of 127 patients, 92 patients (72%) were initially treated with enucleation and 35 (28%) with plaque radiotherapy. In both univariate and multivariate logistic analysis models, the age of the patient (> 50 years), tumour thickness (> 3 mm), and treatment by age interaction were found to be significant factors for development of distant metastasis. In patients younger than 50 years, the method of treatment (enucleation versus plaque radiotherapy) did not significantly affect the risk of metastasis. For those older than 50 years, there was a non-significant trend for patients in the enucleation group to be at a higher risk for metastasis than those in the plaque group. In the enucleation group, patients older than 50 years had a significantly higher incidence of distant metastasis than those younger than 50 years. In the plaque radiotherapy group, there was no significant higher incidence of metastasis in patients younger than 50 years than in those older than 50 years. When a Cox proportional hazards model was used to evaluate the survival rate, there was the same statistically significant effect of treatment by age interaction as was found in the multivariate logistic model on survival time. Moreover, there was a significant effect of treatment by tumour thickness interaction on survival time. Patients in the enucleation group had a better survival rate when the thickness of the tumour was less than 3 mm compared with a tumour of more than 3 mm. There were no apparent effects of tumour thickness on survival for patients treated with plaque radiotherapy. From these results, the authors currently recommend plaque radiotherapy as a viable option to enucleation in patients with juxtapapillary choroidal melanoma.

Entities:  

Mesh:

Year:  1994        PMID: 8123617      PMCID: PMC504711          DOI: 10.1136/bjo.78.2.109

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  10 in total

1.  Comparison of xenon arc and argon laser photocoagulation in the treatment of choroidal melanomas.

Authors:  J A Shields; L C Glazer; W F Mieler; C L Shields; M S Gottlieb
Journal:  Am J Ophthalmol       Date:  1990-06-15       Impact factor: 5.258

2.  Comparison of survival rates for patients with uveal melanoma after treatment with proton beam irradiation or enucleation.

Authors:  J M Seddon; E S Gragoudas; D M Albert; C C Hsieh; L Polivogianis; G R Friedenberg
Journal:  Am J Ophthalmol       Date:  1985-03-15       Impact factor: 5.258

3.  Ocular Melanoma Task Force Report.

Authors:  B J Graham; T D Duane
Journal:  Am J Ophthalmol       Date:  1980-11       Impact factor: 5.258

4.  Current results of proton beam irradiation of uveal melanomas.

Authors:  E S Gragoudas; J Seddon; M Goitein; L Verhey; J Munzenrider; M Urie; H D Suit; P Blitzer; A Koehler
Journal:  Ophthalmology       Date:  1985-02       Impact factor: 12.079

5.  Current alternatives in the management of posterior uvea melanomas.

Authors:  J A Shields; C L Shields; P Shah; P DePotter
Journal:  Trans Pa Acad Ophthalmol Otolaryngol       Date:  1990

Review 6.  Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells.

Authors:  L E Zimmerman; I W McLean; W D Foster
Journal:  Br J Ophthalmol       Date:  1978-06       Impact factor: 4.638

7.  Treatment of juxtapapillary melanomas.

Authors:  P K Lommatzsch; R Lommatzsch
Journal:  Br J Ophthalmol       Date:  1991-12       Impact factor: 4.638

8.  Enucleation vs cobalt plaque radiotherapy for malignant melanomas of the choroid and ciliary body.

Authors:  J J Augsburger; J W Gamel; V F Sardi; R A Greenberg; J A Shields; L W Brady
Journal:  Arch Ophthalmol       Date:  1986-05

Review 9.  Management of posterior uveal melanoma.

Authors:  J A Shields; C L Shields; L A Donoso
Journal:  Surv Ophthalmol       Date:  1991 Nov-Dec       Impact factor: 6.048

10.  Partial lamellar sclerouvectomy for ciliary body and choroidal tumors.

Authors:  J A Shields; C L Shields; P Shah; V Sivalingam
Journal:  Ophthalmology       Date:  1991-06       Impact factor: 12.079

  10 in total
  7 in total

1.  Indications for trans-scleral local resection of uveal melanoma.

Authors:  B Damato; W S Foulds
Journal:  Br J Ophthalmol       Date:  1996-11       Impact factor: 4.638

2.  Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study.

Authors:  Anne Sudaka; Antoine Susini; Cristiana Lo Nigro; Jean-Louis Fischel; Nicolas Toussan; Patricia Formento; Federica Tonissi; Laura Lattanzio; Elvio Russi; Marie-Christine Etienne-Grimaldi; Marco Merlano; Gérard Milano
Journal:  Invest New Drugs       Date:  2012-06-20       Impact factor: 3.850

3.  Multidrug resistance in ocular melanoma.

Authors:  M McNamara; M Clynes; B Dunne; R NicAmhlaoibh; W R Lee; C Barnes; S M Kennedy
Journal:  Br J Ophthalmol       Date:  1996-11       Impact factor: 4.638

4.  Outcomes following Notched Ruthenium-106 Plaque Brachytherapy for Juxtapapillary Choroidal Melanomas.

Authors:  Manvi Manu Sobti; Magdalena Edington; Julie Connolly; David J McLernon; Stefano Schipani; Diana Ritchie; Paul Cauchi; Vikas Chadha
Journal:  Ocul Oncol Pathol       Date:  2021-08-23

5.  Long term visual outcome of radiated uveal melanomas in eyes eligible for randomisation to enucleation versus brachytherapy.

Authors:  D H Char; S Kroll; J M Quivey; J Castro
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

6.  Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate.

Authors:  Masood Naseripour; Ramin Jaberi; Ahad Sedaghat; Zohreh Azma; Marzieh Nojomi; Khalil Ghasemi Falavarjani; Hossein Nazari
Journal:  J Contemp Brachytherapy       Date:  2016-02-09

7.  Small High-Risk Uveal Melanomas Have a Lower Mortality Rate.

Authors:  Rumana N Hussain; Sarah E Coupland; Helen Kalirai; Azzam F G Taktak; Antonio Eleuteri; Bertil E Damato; Carl Groenewald; Heinrich Heimann
Journal:  Cancers (Basel)       Date:  2021-05-08       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.